StockNews.com started coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a report issued on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
A number of other analysts also recently issued reports on the stock. HC Wainwright reaffirmed a buy rating and set a $5.00 price target on shares of AcelRx Pharmaceuticals in a report on Thursday, December 7th. Alliance Global Partners started coverage on shares of AcelRx Pharmaceuticals in a report on Monday, October 2nd. They set a buy rating and a $4.25 price target on the stock.
AcelRx Pharmaceuticals Price Performance
AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.21. The firm had revenue of $0.12 million for the quarter. On average, equities analysts anticipate that AcelRx Pharmaceuticals will post -0.4 EPS for the current year.
Hedge Funds Weigh In On AcelRx Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of AcelRx Pharmaceuticals by 9.1% during the third quarter. Vanguard Group Inc. now owns 171,791 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 14,284 shares during the last quarter. BlackRock Inc. increased its position in AcelRx Pharmaceuticals by 1.0% in the third quarter. BlackRock Inc. now owns 1,947,140 shares of the specialty pharmaceutical company’s stock worth $407,000 after purchasing an additional 19,986 shares during the last quarter. Renaissance Technologies LLC bought a new stake in AcelRx Pharmaceuticals in the first quarter worth $27,000. Susquehanna International Group LLP bought a new stake in AcelRx Pharmaceuticals in the fourth quarter worth $144,000. Finally, Values First Advisors Inc. increased its position in AcelRx Pharmaceuticals by 201.7% in the second quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock worth $136,000 after purchasing an additional 81,854 shares during the last quarter. Hedge funds and other institutional investors own 19.79% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.
- Five stocks we like better than AcelRx Pharmaceuticals
- How to Invest in the Healthcare Sector
- Does UPS stock going down present an opportunity?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The truth behind Williams-Sonoma stock drop
- Manufacturing Stocks Investing
- Is Airbnb a buy on fee increase, international growth?
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.